Cui Lei, Yu Huiping, Sun Qingmei, Miao Yi, Jiang Kuirong, Fang Xiaoping
Department of General Surgery, Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Asia Pac J Oncol Nurs. 2023 Feb 17;10(4):100209. doi: 10.1016/j.apjon.2023.100209. eCollection 2023 Apr.
We aimed to establish and validate the Chinese version of the Pancreatic Cancer Disease Impact (C-PACADI) score for Chinese patients with pancreatic cancer (PC).
This was a methodological and cross-sectional study. We established the C-PACADI score following Beaton's translation guidelines and then included 209 patients with PC to evaluate C-PACADI's reliability and validity.
The Cronbach's alpha coefficient of the C-PACADI score was 0.822. The correlation coefficient between "skin itchiness" score and the total score was 0.224, while the correlation coefficients ranged from 0.515 to 0.688 ( < 0.001) for all the other items. The item content validity index and the scale content validity index, evaluated by eight experts were 0.875 and 0.98, respectively. Regarding concurrent validity, the total score of the C-PACADI score was moderately correlated with the EuroQol-5D (EQ-5D) index and the EQ-5D VAS score ( = -0.738, < 0.01; = -0.667, < 0.01, respectively); the individual-item scores of C-PACADI on pain/discomfort, anxiety, loss of appetite, fatigue, and nausea were strongly associated with the corresponding symptoms of the Edmonton Symptom Assessment System scale ( ranged from 0.879 to 0.916, < 0.01). The known-group validity was demonstrated by C-PACADI's ability to detect significant symptom differences between groups stratified by treatment modalities ( < 0.05) and health status ( < 0.001).
The C-PACADI score is a suitable disease-specific tool for measuring the prevalence and severity of multiple symptoms in the Chinese population with PC.
我们旨在建立并验证适用于中国胰腺癌（PC）患者的中文版胰腺癌疾病影响（C-PACADI）评分。
这是一项方法学和横断面研究。我们按照比顿的翻译指南建立了C-PACADI评分，然后纳入209例PC患者以评估C-PACADI的信度和效度。
C-PACADI评分的克朗巴哈系数为0.822。“皮肤瘙痒”评分与总分的相关系数为0.224，而其他所有项目的相关系数范围为0.515至0.688（P<0.001）。由八位专家评估的项目内容效度指数和量表内容效度指数分别为0.875和0.98。关于同时效度，C-PACADI评分的总分与欧洲五维健康量表（EQ-5D）指数和EQ-5D视觉模拟评分（VAS）得分呈中度相关（分别为r=-0.738，P<0.01；r=-0.667，P<0.01）；C-PACADI在疼痛/不适、焦虑、食欲不振、疲劳和恶心方面的单项评分与埃德蒙顿症状评估系统量表的相应症状密切相关（r范围为0.879至0.916，P<0.01）。通过C-PACADI区分不同治疗方式（P<0.05）和健康状况（P<0.001）分层的组间显著症状差异的能力证明了已知组效度。
C-PACADI评分是一种适用于测量中国PC患者多种症状的患病率和严重程度的疾病特异性工具。
